Bio Association Operates Partnering Platform to Support K-Bio Global Expansion

The Korea Bio Association announced on the 2nd that it will launch a platform where domestic bio and pharmaceutical companies can directly communicate and expand their networks with business development managers in the global bio and pharmaceutical research and development (R&D) sector.

[Photo by Korea Bio Association]

This platform operation is carried out in collaboration with InPart, a French company that already operates a global online partnering platform. Through this, it aims to provide over 640 member companies with opportunities to connect with exclusive assets and partners in the global bio and pharmaceutical fields.

So far, the association has organized various global partnering events, including the Global Mingle program supporting the overseas expansion of domestic bio companies, creating networking opportunities with multinational pharmaceutical companies. Through this collaboration, it plans to actively support the development of new innovative technologies and commercialization for domestic bio companies by providing a continuously accessible network database.

InPart’s partnering platform, "Connect," is widely used by R&D teams and open innovation departments of over 6,500 companies, including the top 25 global pharmaceutical companies and more than 2,000 mid-sized bio pharmaceutical companies, to discover new assets and collaboration partners. Notably, it provides the partnering system for the BIO International Convention, the world’s largest bio event held annually in the U.S. every June, generating numerous success stories.

Through this collaboration, the Bio Association plans to offer a special promotion allowing member companies to use the online partnering platform at a discounted price. Detailed information will be announced later on the association’s website.

Hwang Juri, Head of the Exchange and Cooperation Division at the Bio Association, said, "Through this collaboration, we will further solidify Korea’s reputation for fostering early-stage bio innovation and provide new pathways for Korean bio companies to collaborate internationally with major global pharmaceutical companies."

This content was produced with the assistance of AI translation services.